Repligen Corporation (RGEN) reported third-quarter 2024 adjusted earnings per share of 43 cents, which beat the Zacks Consensus Estimate of 34 cents. The company recorded adjusted earnings of 23 cents per share in the year-ago quarter.Total revenues were $154.9 million, up 10% year over year on a reported basis. Excluding the impact of acquisition revenues and currency exchange, revenues rose 7% organically. The reported figure also beat the Zacks Consensus Estimate of $153.1 million.This increase in total ...

Repligen Corp RGEN released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents.The bioprocessing technology reported sales of $154.87 million, up 10% year-over-year, beating the consensus of $153.23 million.Olivier Loeillot, president and CEO of Repligen, said, "I'm pleased to report strong third-quarter results, made possible by the excellent execution by our team and improving market conditions. We are encouraged to see strengthening CDMO and ...

Repligen (RGEN) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 26.47%. A quarter ago, it was expected that this drug developer would post earnings of $0.33 per share when it actually produced earnings of $0.33, delivering no surprise.Over the last four quarters, the company has surpa ...

WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at three upcoming investor conferences. The UBS Global Healthcare Conference being held November 11-14 in Rancho Palos Verdes, CA. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on Thursday, November 14, at 10:15 a.m. ET.The Stifel Healthcare Conference being held Novembe ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Repligen (RGEN) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may m ...

Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Peptide Therapeutics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Peptide Therapeutics was estimated at US$42.1 Billion in 2023 and is projected to reach US$56.2 Billion by 2030, growing at a CAGR of 4.2% from 2023 to 2030. The development of peptide therapeutics has been greatly accelerated by technological advances, enabling the creation of more stable, potent, and targeted therapies. Peptides, ...

Core Insights - Repligen Corporation has opened the Repligen Training & Innovation Center (RTIC) at its Waltham headquarters to enhance customer engagement and support [1][3] - The RTIC showcases a comprehensive range of Repligen's bioprocessing technologies, including upstream and downstream products, and serves as a hands-on training facility [2][3] - The company is committed to innovation and aims to meet growing customer expectations in the biologics market as it anticipates a return to growth by 2025 [3] Company Developments - The RTIC spans approximately 7,500 square feet within a 55,000 square foot expansion project, which took 20 months to complete [3] - Repligen has also expanded its presence in Europe with a new 80,000 square foot facility in Jüri, Estonia, which serves as a Customer Center of Excellence [4] - The Estonia facility is LEED Silver certified and supports various functions including R&D, engineering, manufacturing, and technical support [4] Product and Technology Focus - The RTIC features a variety of Repligen's bioprocessing technologies, including XCell® ATF, KrosFlo® TFDF® devices, OPUS® pre-packed chromatography columns, and Spectrum® hollow fiber filters [2] - The center will also highlight process analytics technologies such as CTech™ SoloVPE® and FlowVPX® [2] - Repligen's focus areas include Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins, catering primarily to biopharmaceutical developers and CDMOs [5]

Financial Restatement - The restatement will result in an overstatement of Q1 2023 product revenues by $17.3 million and an understatement of Q4 2023 product revenues by $10.7 million, leading to an aggregate overstatement of $6.6 million for the year ended December 31, 2023[8]. - The anticipated financial impact of the restatement includes an understatement of Q1 2024 product revenues by $1.8 million and Q2 2024 product revenues by $4.8 million[8]. - The company will restate its consolidated financial statements for the year ended December 31, 2023, and for the quarterly periods ended March 31, 2023, June 30, 2023, and September 30, 2023[10]. - The company has not yet finalized the quantification of the income tax expense/benefit impact of the restatement for each respective quarterly or annual period[8]. Revenue Guidance - The company reaffirms its full year 2024 revenue guidance, updating the range to $627 million to $642 million, which includes the previously understated $6.6 million in the first half of 2024[9]. Internal Controls - The company identified a material weakness in internal control over financial reporting related to revenue recognition under ASC 606[11]. - The company is undergoing an internal review to assess the effectiveness of its internal controls and may identify further required changes[11]. Operational Impact - The restatement does not impact the company's overall business operations or previously reported cash and cash equivalent balances[5]. - All open purchase order product units were fully delivered to the customer by June 30, 2024, indicating no anticipated impact of the revenue recognition change beyond this date[7]. One-time Payment - The company received a one-time cash payment of $17.3 million in April 2023 due to the cancellation of two COVID-related non-cancellable product purchase orders[6].

Company Overview - Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies and systems that enhance the manufacturing efficiency of biological drugs [3] - The company primarily serves biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide [3] - Key focus areas include Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3] - Corporate headquarters are located in Waltham, Massachusetts, with manufacturing sites in the U.S. and additional locations in Estonia, France, Germany, Ireland, the Netherlands, and Sweden [3] Upcoming Events - Repligen Corporation will present at the Wells Fargo Healthcare Conference from September 4-6, 2024, in Boston [1] - Olivier Loeillot, President and CEO, will participate in an analyst-led discussion on September 6 at 8:45 a.m. ET [1] - A live webcast of the conference presentation will be available on Repligen's Investor Relations website and will be accessible for replay for a limited time after the event [2]

The bioprocessing market is preparing for a recovery. The bioprocessing market is about to recover. That's the conclusion from Repligen's (RGEN -1.00%) secondquarter earnings report released earlier in the week and the reason for the stock's 17.7% ascendancy in the week to Friday morning. Repligen and Danaher are seeing budding shoots of recovery A positive view of Repligen's recovery is supported when examining Danaher's recent results, released a week earlier. Danaher is a much larger company selling life ...